WO2003039592A3 - Zelluläre impfstoffe mit adjuvanzien - Google Patents

Zelluläre impfstoffe mit adjuvanzien Download PDF

Info

Publication number
WO2003039592A3
WO2003039592A3 PCT/EP2002/012527 EP0212527W WO03039592A3 WO 2003039592 A3 WO2003039592 A3 WO 2003039592A3 EP 0212527 W EP0212527 W EP 0212527W WO 03039592 A3 WO03039592 A3 WO 03039592A3
Authority
WO
WIPO (PCT)
Prior art keywords
adjuvants
cellular vaccines
composition
relates
tumours
Prior art date
Application number
PCT/EP2002/012527
Other languages
English (en)
French (fr)
Other versions
WO2003039592A2 (de
Inventor
Claudia Breidenstein
John Nieland
Original Assignee
Medigene Ag
Claudia Breidenstein
John Nieland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Claudia Breidenstein, John Nieland filed Critical Medigene Ag
Priority to CA002466698A priority Critical patent/CA2466698A1/en
Priority to US10/494,716 priority patent/US20050085433A1/en
Priority to EP02802659A priority patent/EP1441759A2/de
Publication of WO2003039592A2 publication Critical patent/WO2003039592A2/de
Publication of WO2003039592A3 publication Critical patent/WO2003039592A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft eine Zusammensetzung für die Impfung von Tumoren enthaltend zumindest eine Tumorzelle, die zumindest ein Cytokin, Chemokin und/oder ein co-stimulierendes Molekül exprimiert und eine wirksame Menge von zumindest einem Adjuvans, sowie die Verwendung einer derartigen Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung von Tumoren.
PCT/EP2002/012527 2001-11-09 2002-11-08 Zelluläre impfstoffe mit adjuvanzien WO2003039592A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002466698A CA2466698A1 (en) 2001-11-09 2002-11-08 Cellular vaccines comprising adjuvants
US10/494,716 US20050085433A1 (en) 2001-11-09 2002-11-08 Cellular vaccines comprising adjuvants
EP02802659A EP1441759A2 (de) 2001-11-09 2002-11-08 Zelluläre impfstoffe mit adjuvanzien

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33249701P 2001-11-09 2001-11-09
US60/332,497 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003039592A2 WO2003039592A2 (de) 2003-05-15
WO2003039592A3 true WO2003039592A3 (de) 2003-10-23

Family

ID=23298485

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2002/012526 WO2003039591A2 (de) 2001-11-09 2002-11-08 Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
PCT/EP2002/012527 WO2003039592A2 (de) 2001-11-09 2002-11-08 Zelluläre impfstoffe mit adjuvanzien

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012526 WO2003039591A2 (de) 2001-11-09 2002-11-08 Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle

Country Status (4)

Country Link
US (1) US20050085433A1 (de)
EP (2) EP1441759A2 (de)
CA (2) CA2466698A1 (de)
WO (2) WO2003039591A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699480B1 (de) * 2003-12-30 2011-06-15 Mologen AG Allogenes tumortherapeutikum
WO2009156994A1 (en) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Ccl20-specific antibodies for cancer therapy
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
PL2482849T3 (pl) 2009-09-30 2018-11-30 Memorial Sloan-Kettering Cancer Center Skojarzona immunoterapia w leczeniu nowotworu
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ME03819B (de) 2015-03-23 2021-04-20 Jounce Therapeutics Inc Antikörper gegen icos
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
KR20180118198A (ko) * 2016-03-18 2018-10-30 난트셀, 인크. 수지상 세포 감염을 위한 멀티모달 벡터(multimodal vector for dendritic cell infection)
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3497128A2 (de) 2016-08-09 2019-06-19 Kymab Limited Anti-icos-antikörper
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
CN114807229B (zh) * 2022-05-27 2024-09-24 中国科学院长春应用化学研究所 细胞膜、纳米疫苗及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042855A1 (en) * 1997-03-21 1998-10-01 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines by using hsv amplicon vectors
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0869803B1 (de) * 1995-12-28 2003-04-16 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe
DE19608751B4 (de) * 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042855A1 (en) * 1997-03-21 1998-10-01 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines by using hsv amplicon vectors
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BJORKDAHL O ET AL: "VACCINATION WITH B16 MELANOMA CELLS EXPRESSING A SECRETED FORM OF INTERLEUKIN-1BETA INDUCES TUMOR GROWTH INHIBITION AND AN ENHANCED IMMUNITY AGAINST THE WILD-TYPE B16 TUMOR", CANCER GENE THERAPY, NORWALK, CT, US, vol. 7, no. 10, October 2000 (2000-10-01), pages 1365 - 1374, XP001098771, ISSN: 0929-1903 *
NOMURA T ET AL: "ENHANCEMENT OF ANTI-TUMOR IMMUNITY BY TUMOR CELLS TRANSFECTED WITH THE SECONDARY LYMPHOID TISSUE CHEMOKINE EBI-1-LIGAND CHEMOKINE AND STROMAL CELL-DERIVED FACTOR-1ALPHA CHEMOKINE GENES", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 91, 2001, pages 597 - 606, XP002950173, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
US20050085433A1 (en) 2005-04-21
WO2003039591A2 (de) 2003-05-15
WO2003039592A2 (de) 2003-05-15
EP1441759A2 (de) 2004-08-04
WO2003039591A3 (de) 2004-03-11
EP1441758A2 (de) 2004-08-04
CA2466530A1 (en) 2003-05-15
CA2466698A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
MY129263A (en) Vaccine composition
WO2005009355A3 (en) Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
IL155283A0 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
WO2003051401A3 (de) Stabilisierte mrna tumor-vakzine
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
GB0109297D0 (en) Vaccine
WO2002087494A3 (en) Novel vaccine
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005007673A3 (en) Immunogenic peptides
HK1041831A1 (en) Tumor vaccines
GB2444676A (en) Adjuvanted vaccine
WO2003093298A3 (en) Immunogenic peptides
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2002040518A8 (fr) Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur ou adjuvant
SG147465A1 (en) Vaccine
EP1303300A4 (de) Zusammensetzungen und methoden zur behandlung von candidosen
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
MY127452A (en) Vaccines.
WO2007025276A3 (en) Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002802659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2466698

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002802659

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10494716

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002802659

Country of ref document: EP